ADS-ADEA 2015* , ,
Presentations this author is a contributor to:
Five weeks of resveratrol supplementation has no effect on GLP-1 secretion, gastric emptying, or glycemic control in type 2 diabetes (#375)
2:00 PM
Michelle J Bound
ADEA Poster Viewing One
Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males (#70)
4:00 PM
Tongzhi Wu
ADS Clinical Orals: Gut and Glycaemia
The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial. (#71)
4:15 PM
Chinmay S Marathe
ADS Clinical Orals: Gut and Glycaemia
Effects of exenatide on the blood pressure and heart rate responses to intraduodenal glucose in type 2 diabetes (#168)
4:30 PM
Chinmay S Marathe
ADS Clinical Orals: Therapies for Type 2 Diabetes
Increased Capacity for Intestinal Serotonin Release in Obese and Diabetic Humans (#8)
9:00 AM
Richard L Young
ADS Clinical Orals: Obesity